Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LongeveronLGVN +1.83%55 3-Year EBITDA Growth Rate is 46.40% as of Jun. 2026. GuruFocus rates LGVN with a GF Score™ of 55/100 and a GF Value™ of $3.14 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,124 Biotechnology companies, Longeveron ranks better than 83.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Longeveron was 46.40% per year. The lowest was -74.80% per year. And the median was -34.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Longeveron 3-Year EBITDA Growth Rate Related Terms
LGVN vs AKTX, COCP, ABVC: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Longeveron's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longeveron 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longeveron's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Longeveron's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 46.40% mean?
Longeveron (LGVN) has a 3-Year EBITDA Growth Rate of 46.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Longeveron and its competitors. According to the industry distribution chart, Longeveron ranks #190 out of 1124 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Longeveron's 3-Year EBITDA Growth Rate too high?
Longeveron's current 3-Year EBITDA Growth Rate is 46.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Longeveron's value of 46.40% is 216.7% above this industry median. Based on the distribution chart, Longeveron ranks #190 out of 1124 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longeveron has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's 3-Year EBITDA Growth Rate compare to AKTX and COCP?
According to the Biotechnology industry distribution chart, Longeveron ranks #190 out of 1124 companies for 3-Year EBITDA Growth Rate. This places Longeveron in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.65. Longeveron's value of 46.40% is 216.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longeveron's current 3-Year EBITDA Growth Rate of 46.40% is 216.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Longeveron and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longeveron's current 3-Year EBITDA Growth Rate is 46.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.14, compared to a current price of $6.99 — trading 122.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 46.40% and 216.7% above the Biotechnology industry median of 14.65. Longeveron's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Longeveron (LGVN), the current 3-Year EBITDA Growth Rate is 46.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longeveron (LGVN) Overvalued in 2026?
Based on GuruFocus' analysis, Longeveron stock appears to be overvalued.
The current stock price of $6.99 is trading 122.5% above its estimated GF Value™ of $3.14.
GuruFocus considers Longeveron to be Significantly Overvalued.
Key valuation signals for LGVN:
3-Year EBITDA Growth Rate: 46.40%
GF Value™: $3.14 vs. price of $6.99 (122.5% above fair value)
Industry Position: 216.7% above the Biotechnology median (#190 of 1124)
No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
55GF Score
Get the complete analysis for LGVN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LGVN has been successfully added to your 
